CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (6,250)	$ (2,864)	$ (1,107)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	5,115	3,933	1,817
Amortization of deferred financing costs and debt discount	1,279	2,148	259
Payment of imputed interest on debt	(3,893)	(105)	(13)
Deferred taxes	498	290	(422)
Issuance of common stock warrants		16	31
Stock-based compensation	4,250	565	254
Change in fair value of warrant liability	(639)	2,786	269
Change in fair value of acquisition-related contingent consideration	(338)	(2,059)	790
Change in fair value of acquisition-related consideration	55
Loss on extinguishment of debt	6,411
Write-off in-process software development costs			63
Other noncash items		(10)
Changes in operating assets and liabilities, net of effect from acquisitions:
Accounts receivable, net	(633)	(1,711)	(1,388)
Inventories	(607)	(264)	(792)
Rebates receivable	752	(96)	(715)
Prepaid expenses and other current assets	(929)	(259)	(77)
Other assets	1	(4)	(30)
Acquisition-related contingent consideration		(610)	(60)
Accounts payable	665	440	1,383
Accrued expenses and other liabilities	(1,168)	1,060	604
Other long-term liabilities	2,205		4
Net cash provided by operating activities	6,774	3,256	870
Cash flows from investing activities:
Purchases of property and equipment	(3,813)	(234)	(230)
Software development costs	(1,854)	(940)	(738)
Purchase of intangible assets	(29)
Change in restricted cash	200	300	(500)
Purchase of businesses, net of cash acquired	(5,400)	(2,403)	(13,448)
Net cash used in investing activities	(10,896)	(3,277)	(14,916)
Cash flows from financing activities:
Proceeds from exercise of stock options	153	12	59
Payments for debt financing costs	(1,521)	(69)	(212)
Proceeds from notes payable to related parties			100
Repayments of notes payable to related parties	(250)	(354)	(175)
Borrowings on line of credit	6,000	10,000
Repayments of line of credit	(16,000)	(6,860)
Payments of acquisition-related consideration	(180)	(1,895)	(487)
Repayment of note payable related to acquisition	(14,337)
Payments of initial public offering costs	(3,346)	(481)
Payments of contingent consideration	(1,895)	(267)	(440)
Proceeds from long-term debt	30,000		15,000
Repayments of long-term debt	(47,369)	(2,161)	(1,704)
Proceeds from issuance of common stock under initial public offering, net of underwriting costs	55,186
Net cash provided by (used in) financing activities	6,441	(2,075)	12,141
Net increase (decrease) in cash	2,319	(2,096)	(1,905)
Cash, beginning of period	2,026	4,122	6,027
Cash, end of period	4,345	2,026	4,122
Supplemental disclosure of cash flow information
Acquisition of equipment under capital leases	1,605	373	326
Additions to property, equipment, and software development purchases included in accounts payable	373	46	53
Deferred offering costs included in accounts payable	132	1,817
Cash paid for interest	8,457	2,409	1,080
(Decretion) accretion of redeemable convertible preferred stock to redemption value	$ (2,439)	$ 9,966	3,884
Fair value of promissory notes entered into connection with Medliance acquisition			14,347
Fair value of preferred stock warrants issued to lender			$ 1,835